A multicenter phase III trial comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer

Our purpose was to determine the response rate and median and overall survival of gemcitabine as monotherapy versus gemcitabine plus irinotecan in advanced or metastatic pancreatic cancer. Patients with histologically or cytologically confirmed adenocarcinoma who were chemotherapy and radiotherapy n...

Descripción completa

Detalles Bibliográficos
Autores principales: Stathopoulos, G P, Syrigos, K, Aravantinos, G, Polyzos, A, Papakotoulas, P, Fountzilas, G, Potamianou, A, Ziras, N, Boukovinas, J, Varthalitis, J, Androulakis, N, Kotsakis, A, Samonis, G, Georgoulias, V
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2006
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360678/
https://www.ncbi.nlm.nih.gov/pubmed/16909140
http://dx.doi.org/10.1038/sj.bjc.6603301

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360678/
https://www.ncbi.nlm.nih.gov/pubmed/16909140
http://dx.doi.org/10.1038/sj.bjc.6603301

Ejemplares similares